Bioretec Ltd. Achieves CE Mark for RemeOs™ Trauma Screw Portfolio
Bioretec Ltd. has successfully completed the CE mark approval process for its RemeOs™ Trauma Screw product line, marking a significant advancement for the company. This approval allows Bioretec to immediately launch its products across Europe, tapping into the expansive distribution network previously established for the company's Activa products.
The RemeOs™ Trauma Screws, made from a unique magnesium alloy, represent a revolutionary approach in absorbable orthopedic devices, promising improved surgical outcomes. These screws integrate traditional surgical practices with absorbable materials, emphasizing patient-centric care and enhancing the overall efficiency of healthcare delivery. Remarkably, the osteopromotive nature of these screws supports natural bone healing as they dissolve, eliminating the need for subsequent surgical removal of hardware, thus offering a cost-effective solution.
Market Implications of CE Mark Approval
The CE mark opens new doors for Bioretec, particularly as it covers numerous clinical applications for both adult and pediatric patients. Indications for use span from the treatment of bone fractures to fixation procedures for osteotomies, addressing common injuries such as fractures in the ankle and elbow.
The RemeOs™ product line features four specialized variants, each designed with trauma and pediatric surgeons in mind. From fully threaded compression screws to cannulated options, these products are versatile enough to accommodate varying bone sizes and shapes. With diameters ranging from 2 to 4 mm and lengths from 8 to 50 mm, the RemeOs™ portfolio is tailored to meet the diverse surgical needs of patients.
Global Market Opportunities and Expansion
In addition to European markets, the CE mark also assists in accelerating Bioretec's strategy for global expansion, as it is recognized in numerous other countries for local registration processes. This recognition streamlines market access and regulatory compliance, facilitating quicker entry into new regions.
Furthermore, this approval allows Bioretec to gather real-world evidence and clinical data from reputable European centers. Backed by an esteemed Scientific Advisory Board and recognized thought leaders in the field, Bioretec intends to use this data to enhance its FDA registration efforts and expand its offerings in the U.S. market.
CEO's Vision for the Future
Alan Donze, CEO of Bioretec, expressed enthusiasm regarding the approval, stating that it symbolizes a pivotal chapter in the company’s journey. With the solid foundation of support from distributors in Europe and a medical community familiar with their technologies, Bioretec anticipates that RemeOs products will redefine standards in treating bone fractures, ultimately improving life quality for patients worldwide.
The Orthopedic Trauma Market Landscape
The global orthopedic trauma device market is poised for growth, valued at approximately USD 9 billion. The increasing prevalence of injuries and advancements in surgical techniques are fueling demand, with a pronounced market shift towards minimally invasive procedures. These trends are essential as the aging population seeks solutions to maintain mobility and overall health.
Bioretec's Unique Offerings
Bioretec’s RemeOs range not only meets existing clinical challenges but is also flexible enough to adapt to evolving surgical practices. These implants' innovative absorbable nature supports a move toward value-based healthcare, aligning clinical outcomes with economic considerations.
Bioretec aims to address the needs of trauma care clinicians in both adult and pediatric demographics, ensuring a comprehensive portfolio that anticipates and responds to market demands.
Contact Information
For further inquiries, contact:
Alan Donze, CEO, +1 619 977 5285
Johanna Salko, CFO, +358 40 754 8172
Frequently Asked Questions
What is the significance of Bioretec’s CE mark approval?
The CE mark approval allows Bioretec to market its RemeOs™ Trauma Screws in Europe, enhancing its presence in the orthopedic device market.
What materials are RemeOs™ Trauma Screws made from?
The screws are manufactured from a proprietary magnesium alloy known for its strength and absorbability, promoting superior healing outcomes.
How does the CE mark affect global expansion for Bioretec?
The CE mark simplifies the local registration process in many countries, allowing Bioretec to expand its market reach more efficiently.
What types of surgical needs do RemeOs™ products address?
These products cater to various surgical needs, particularly in treating bone fractures and performing fixation after osteotomies.
How can patients benefit from the use of RemeOs™ products?
Patients benefit from reduced surgical interventions since the absorbable screws eliminate the need for hardware removal, supporting quicker recovery times.
